PDCD1 and cancer: Therefore, designing small molecule inhibitors of the PD-1/PD-L1 complex with physicochemical properties enabling pH-dependent binding activity could be a promising strategy to improve the efficacy, as well as the specificity, of immunotherapy against types of cancer endowed with dysregulated pH conditions in the tumor microenvironment.